Sanyou Bio

A high-tech biopharmaceutical company with a business model driven by AI technology, supported by intelligent R&D platforms and guided by its innovative drug pipeline. sanyoubio.com

Funding

• nearly RMB 100 million Series C, announced November 9, 2026. Sole investor named: Zero2IPO Industry Investment. The company says the round funds its AI-driven drug R&D system, whose core engine is the Sanyou AI-Drug Accelerator (SAI-DA). Listed in the AI startup funding roster for November 8–14, 2026. Sources: PR Newswire (company release), Fineline Cube (flcube.com).

Whether AI names Sanyou Bio

• Machine Relations Index: Not cited in any Machine Relations Index answer, May 10, 2026 to November 14, 2026.

A company counts when an AI answer names it or cites its website. Answers vary from run to run, so each count is a dated sample.

Related records

Closest rounds in the roster for November 8–14, 2026: LangChain ($300 million Series C, November 13, 2026), Q-CTRL (US$290 million Series C, November 12, 2026), Fractile ($720 million Series C, November 11, 2026), Finite State ($27 million Series C, November 10, 2026), Nominal ($240 million Series C, November 9, 2026), Morsa ($1.5 million pre-seed, November 13, 2026).

Sources

• PR Newswire (company release)
• Fineline Cube (flcube.com)

Every fact on this page links its source. Corrections need a public source: see Contact.